

Press release April 1st, 2016:

CENTOGENE appoints new CFO, Richard Stoffelen, to take company through next phase of growth

Rostock, Germany: CENTOGENE AG, a world-leading company in the characterization and diagnostic of rare hereditary diseases, announces the appointment of Richard Stoffelen as its Chief Financial Officer. Richard joined CENTOGENE April 1st, 2016, providing international expertise in global financial topics and leadership in the IPO plans of CENTOGENE.

“Richard has over 25 years of broad experience with international audit functions covering the full width of governance and risk concepts. His expertise, combined with his extensive change management (communication) skills will ensure that the finance organization will enable the company to continue to drive growth, capitalizing on the growing worldwide demand for genetic testing which in turn will drive further efficiency, financial governance and risk management across the full spectrum of the financial operations. His huge experience and know-how, also in IPO processes, will support us in our further global growth”, stated Prof. Arndt Rolfs, CEO CENTOGENE AG.

Richard Stoffelen previously served as Head of Internal Audit at Holcim, a listed multinational company in Switzerland; from 1991 to 2013 he was active in different Audit- and Management-positions at a multitude of locations with KPMG, eg Chicago, Frankfurt, Hong Kong and the Netherlands. He graduated as a Dutch CPA with the NBA and Tilburg University-the Netherlands, with further executive education programs at Harvard Business School, Insead (Executive MBA), IMD and IESE.

Actual CFO Christine Uekert will remain with the company as Senior VP Finance and Administration.

Richard commented, "I am honored to have the opportunity to join CENTOGENE AG and help transform the company into the global finance markets and business models based on the excellent work already being done by my colleague, Christine Uekert, the former CFO who decided to move in the new position due to private reasons. Together we will be able to start the planned IPO process, to complete attractive strategic deals, to raise capital, and to manage the further expansion of Centogene. I'm thrilled to work in such a fascinating environment with Arndt Rolfs, the Board and the entire management team, in guiding genetics into a new era."

About CENTOGENE

CENTOGENE is a worldwide leader in the field of genetic diagnostics for rare hereditary diseases - with the largest test portfolio worldwide. Testing samples from over 90 different countries allows CENTOGENE a unique insight into epidemiological basis of hereditary disorders, which is crucial in the medical result interpretation process. The company is strictly focusing on offering quality molecular genetic diagnostics, underlined by its multiple international accreditations (ISO, CAP, CLIA). CENTOGENE's in depth medical expertise is supported by the application of cutting-edge technologies including next generation sequencing, whole exome sequencing (CentoXome®), whole genome sequencing (CentoGenome™) and innovative biomarkers for selected diseases. CENTOGENE has developed a comprehensive mutation database (CentoMD®) that is pillar to offering high quality diagnostic reporting and medical interpretation, thoroughly interpret each patient's sequence data. With a multi-years' experience in molecular diagnostics, EXTAN® kits are the result of intensive research and development, offering a validated solution to laboratories worldwide to expand their test portfolio reliably. Beside diagnostic services for individual patients, CENTOGENE is also a pivotal partner to multiple renowned industrial partners worldwide. CENTOGENE has affiliations in Germany, India, Canada, Austria and the United Arab Emirates.

For more information, please visit www.centogene.com